Kymera Therapeutics IncKYMR
ASignal's systematic analysis rates KYMR as Neutral.
Reflects the latest available analysis · analyzed Aug 30, 2026
The case on KYMR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (466.4% YoY)
- High cash position ($690.99M) with low debt ($78.56M)
- Debt-to-equity ratio of 0.05x indicates strong financial health
- Current ratio of 10.34x reflects strong liquidity
- MACD slightly above signal line, indicating potential bullish momentum
- Negative profit, operating, and gross margins
- Negative free cash flow (-$144.07M)
- Negative enterprise value to EBITDA (-27.10x)
- Forward P/E of -24.05x suggests unprofitability
- Price near upper Bollinger Band with RSI at 61.49, indicating potential overextension
See the full verdict on KYMR
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes KYMR
Most investors never get a second opinion, let alone several. ASignal runs KYMR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.